MabVax Therapeutics Holdings, Inc. to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City

SAN DIEGO, Sept. 7, 2017 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced that David Hansen, MabVax's President and Chief Executive Officer will present at the 19^th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC on Tuesday, September 12, 2017 at 2:35 PM ET. The conference is being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City.

As part of his presentation, Mr. Hansen will provide a corporate overview and a clinical update on the Company's lead clinical development program, MVT-1075, a fully human antibody radioimmunotherapy (RIT) for the treatment of CA19-9 positive malignancies including pancreatic, colon and lung cancers, currently in Phase 1 development. Additionally, Mr. Hansen will discuss the results of the Company's Phase 1 clinical trials of both the fully human IgG1 monoclonal antibody (mAb) antibody MVT-5873, which was able to demonstrate safety; and the Company's PET imaging diagnostic product MVT-2163, which was able to demonstrate specificity and establish the dosing strategy for both the imaging agent and for the RIT program.  Together, these two clinical trials in which a total of 50 patients were treated, set the stage for developing MVT-1075.

The Company recently announced that it has engaged Greenhill & Co. (NYSE: GHL) to assist the Company in evaluating strategic options currently being considered by the Company to improve stockholder value, as well as identifying new opportunities which could include the acquisition of MabVax by another company, the sale or divestiture of specific assets coupled with a reverse merger, merging with another company, or licensing of selected technologies, or a combination of selected divestitures followed by a reverse merger. 

In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

A live audio webcast of the presentation will be available on the Events page of the Investor section of the Company's website (www.mabvax.com). A webcast replay will be available approximately two hours after the presentation ends and will be accessible for 90 days following the live presentation.

About MabVax:

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer. Our antibody MVT-5873, is a fully human IgG1 monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an epitope on CA19-9, and is currently in Phase 1 clinical trials as a therapeutic agent for patients with pancreatic cancer and other CA19-9 positive tumors. CA19-9 is expressed in over 90% of pancreatic cancers and in other diseases including small cell lung and GI cancers. CA19-9 plays an important role in tumor adhesion and metastasis, and is a marker of an aggressive cancer phenotype. CA19-9 serum levels are considered a valuable adjunct in the diagnosis, prognosis and treatment monitoring of pancreatic cancer. With our collaborators including Memorial Sloan Kettering Cancer Center, Sarah Cannon Research Institute, Honor Health and Imaging Endpoints, we have treated 50 patients with either our therapeutic antibody designated as MVT-5873 or our PET imaging diagnostic product designated as MVT-2163 in Phase 1 clinical studies, and demonstrated early safety and specificity for the target. Patient dosing has commenced for our lead development program in Phase 1 clinical study of the Company's radioimmunotherapy product MVT-1075. For additional information, please visit the Company's website, www.mabvax.com.

Forward Looking Statements:

This press release on announcing the closing of our registered direct offering contains "forward-looking statements" regarding matters that are not historical facts, including statements relating to the Company's clinical trials and product development pipeline. We have no assurance that all the product development pipeline will be fully developed by the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the fiscal year ended December 31, 2016, as amended and supplemented from time to time and the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. The parties do not undertake any obligation to update forward-looking statements contained in this press release.

Investor Contact:

Jenene Thomas
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475
Email: jtc@jenenethomascommunications.com

View original content with multimedia:http://www.prnewswire.com/news-releases/mabvax-therapeutics-holdings-inc-to-present-at-the-19th-annual-rodman--renshaw-global-investment-conference-in-new-york-city-300513358.html

SOURCE MabVax Therapeutics